menu
    • menu
    [{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ripple Therapeutics \/ Glaukos","highestDevelopmentStatusID":"3","companyTruncated":"Ripple Therapeutics \/ Glaukos"},{"orgOrder":0,"company":"Evotec","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Evotec \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ Eurostars","highestDevelopmentStatusID":"3","companyTruncated":"Amarna Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Turn Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Hanall Biopharma \/ Turn Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"Hanall Biopharma \/ Turn Biotechnologies"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Kodiak Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Kodiak Sciences"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Beam Therapeutics \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Beam Therapeutics \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Aavnergene","sponsor":"Neurophth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Aavnergene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Aavnergene \/ Neurophth Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Aavnergene \/ Neurophth Therapeutics"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Shape Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Shape Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Tenpoint Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"3","companyTruncated":"Tenpoint Therapeutics \/ British Patient Capital"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nona Biosciences

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Nona Biosciences

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Kodiak Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Nona, Kodiak Partner on Antibody Therapies for Ophthalmic Diseases

                            Details : The partnership aims to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona's proprietary Harbour Mice fully human antibody platform.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Kodiak Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amarna Therapeutics

                            Netherlands arrow
                            AAN
                            Not Confirmed

                            Amarna Therapeutics

                            Netherlands arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Eurostars

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Phenocell, Amarna Win Grant To Study Gene Therapy for Dry AMD Using Retinal Model

                            Details : Eurostars' funding will support their collaboration to validate Amarna's patented gene therapy platform using a novel and advanced cellular disease model for Dry AMD.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eurostars

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ripple Therapeutics

                            Canada arrow
                            AAN
                            Not Confirmed

                            Ripple Therapeutics

                            Canada arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukos

                            Details :

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hanall Biopharma

                            South Korea arrow
                            AAN
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Turn Biotechnologies

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            HanAll Signs Licensing Agreement with Turn Biotechnologies for Eye and Ear Treatments

                            Details : The collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Turn Biotechnologies

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            AAN
                            Not Confirmed

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : British Patient Capital

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered C...

                            Details : Tenpoint will use the net proceeds to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : British Patient Capital

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shape Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Shape Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : $1,500.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Otsuka Collaborates with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases

                            Details : The companies will collaborate to apply ShapeTX’s AAVid™ capsid discovery platform and transgene engineering technology along with Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatment options for people living w...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : $1,500.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Evotec

                            Germany arrow
                            AAN
                            Not Confirmed

                            Evotec

                            Germany arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Evotec Enters iPSC-Based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology

                            Details : Through phenotypic screening of human iPSC-derived cells, supported by Evotec’s PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic in...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 25, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Beam Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Beam Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Apellis Pharmaceuticals

                            Deal Size : $75.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Apellis and Beam Therapeutics Enter Research Collaboration to Apply Base Editing to Discover Novel Therapies f...

                            Details : Collaboration combines Apellis’ expertise in complement with Beam’s proprietary base editing platform. Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $50.0 million

                            June 30, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Apellis Pharmaceuticals

                            Deal Size : $75.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aavnergene

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Aavnergene

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Neurophth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy

                            Details : Subject to the terms of the agreement, Neurophth will make an initial cash payment to AAVnerGene to test ~100 AAV capsids. Within 6-12 months upon receiving the AAV capsids, Neurophth is responsible for completing the preclinical studies on these capsids...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 19, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Neurophth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth